TMDX

TMDX

USD

TransMedics Group Inc. Common Stock

$121.176+0.866 (0.719%)

Echtzeitkurs

Healthcare
Medizinprodukte
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$120.310

Hoch

$125.220

Tief

$119.000

Volumen

1.03M

Unternehmensfundamentaldaten

Marktkapitalisierung

4.1B

Branche

Medizinprodukte

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

1.00M

Börse

NGM

Währung

USD

52-Wochen-Spanne

Tief $55Aktuell $121.176Hoch $145.5

Ähnliche Nachrichten

PR Newswire

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

Mehr anzeigen
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Analyst Upgrades

Canaccord Genuity Maintains Buy on TransMedics Group, Raises Price Target to $147

Canaccord Genuity analyst William Plovanic maintains TransMedics Group with a Buy and raises the price target from $142 to $147.

Mehr anzeigen
Canaccord Genuity Maintains Buy on TransMedics Group, Raises Price Target to $147
Analyst Upgrades

Piper Sandler Maintains Overweight on TransMedics Group, Lowers Price Target to $140

Piper Sandler analyst Matt O'Brien maintains TransMedics Group with a Overweight and lowers the price target from $145 to $140.

Mehr anzeigen
Piper Sandler Maintains Overweight on TransMedics Group, Lowers Price Target to $140
Analyst Upgrades

Needham Upgrades TransMedics Group to Buy, Announces $148 Price Target

Needham analyst Mike Matson upgrades TransMedics Group from Hold to Buy and announces $148 price target.

Mehr anzeigen
Needham Upgrades TransMedics Group to Buy, Announces $148 Price Target
Analyst Upgrades

Canaccord Genuity Maintains Buy on TransMedics Group, Maintains $142 Price Target

Canaccord Genuity analyst William Plovanic maintains TransMedics Group with a Buy and maintains $142 price target.

Mehr anzeigen
Canaccord Genuity Maintains Buy on TransMedics Group, Maintains $142 Price Target
Analyst Upgrades

Jefferies Initiates Coverage On TransMedics Group with Buy Rating, Announces Price Target of $145

Jefferies analyst Young Li initiates coverage on TransMedics Group with a Buy rating and announces Price Target of $145.

Bleiben Sie auf dem Laufenden

Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.